217 related articles for article (PubMed ID: 35580546)
21. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
23. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
Rech MA; Masic D; Hammond DA
West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
[TBL] [Abstract][Full Text] [Related]
24. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
[TBL] [Abstract][Full Text] [Related]
25. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
Dybdahl D; Walliser G; Chance Spalding M; Pershing M; Kincaid M
Am J Emerg Med; 2019 Oct; 37(10):1907-1911. PubMed ID: 30651183
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
[TBL] [Abstract][Full Text] [Related]
28. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
29. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
[TBL] [Abstract][Full Text] [Related]
30. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
[TBL] [Abstract][Full Text] [Related]
31. Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage.
Townsend B; Slechta J; Gilbert BW
Am J Emerg Med; 2024 Feb; 76():136-139. PubMed ID: 38071882
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
34. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
[TBL] [Abstract][Full Text] [Related]
35. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
36. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
[TBL] [Abstract][Full Text] [Related]
37. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
[TBL] [Abstract][Full Text] [Related]
38. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
39. Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.
Fischer D; Sorensen J; Fontaine GV
Neurocrit Care; 2018 Feb; 28(1):43-50. PubMed ID: 28612131
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]